Seligmann, J. F., Elliott, F., Jacobs, B., Hatch, A. J., Sibley, A., Richman, S., … Nixon, A. B. (2015). HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In Journal of Clinical Oncology (Vol. 33, pp. 3583–3583). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.3583

Seligmann, Jenny F., Faye Elliott, Bart Jacobs, Ace Joseph Hatch, Alexander Sibley, Susan Richman, Chen Jiang, et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).” In Journal of Clinical Oncology, 33:3583–3583. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3583.

Seligmann JF, Elliott F, Jacobs B, Hatch AJ, Sibley A, Richman S, et al. HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3583–3583.

Seligmann, Jenny F., et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 3583–3583. Crossref, doi:10.1200/jco.2015.33.15_suppl.3583.

Seligmann JF, Elliott F, Jacobs B, Hatch AJ, Sibley A, Richman S, Jiang C, Barrett J, Owzar K, Quirke P, Hurwitz H, Seymour MT, Nixon AB. HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3583–3583.